Elias Joby H, Olney Leo W, Frederick Paul M, Yokote Megumi, Herur Jagadeesh
Clinical Pharmacy, Western Health, Melbourne, AUS.
Psychiatry, Western Health, Melbourne, AUS.
Cureus. 2024 Sep 29;16(9):e70457. doi: 10.7759/cureus.70457. eCollection 2024 Sep.
Many medications have established interactions with warfarin, potentially affecting international normalized ratio (INR) levels and increasing the risk of bleeding complications. We present the case of a 74-year-old female inpatient with late-onset schizophrenia who was initiated on brexpiprazole while concurrently receiving warfarin therapy for a ventricular thrombus. Despite INR levels being within a range of 1.8 to 2.7 prior to brexpiprazole initiation, the patient's INR increased sharply to 6 within five days, leading to a potential gastrointestinal bleed that required medical admission. While the manufacturer's in-vitro studies suggest that brexpiprazole does not displace warfarin from albumin, both drugs exhibit greater than 99% protein binding. This case highlights the critical need for close monitoring of INR levels when initiating brexpiprazole in patients on warfarin therapy, due to the potential for warfarin displacement from plasma proteins and subsequent bleeding complications. This interaction warrants further exploration, and clinicians should exercise caution when using these medications concomitantly.
许多药物已证实与华法林存在相互作用,可能影响国际标准化比值(INR)水平并增加出血并发症的风险。我们报告一例74岁晚发性精神分裂症女性住院患者的病例,该患者在接受华法林治疗心室血栓的同时开始使用布雷哌唑。在开始使用布雷哌唑之前,患者的INR水平在1.8至2.7之间,但在五天内INR急剧升至6,导致可能的胃肠道出血,需要住院治疗。虽然制造商的体外研究表明布雷哌唑不会从白蛋白上置换华法林,但两种药物的蛋白结合率均大于99%。该病例突出表明,在接受华法林治疗的患者中开始使用布雷哌唑时,密切监测INR水平至关重要,因为华法林有可能从血浆蛋白上被置换出来,继而引发出血并发症。这种相互作用值得进一步探究,临床医生在同时使用这些药物时应谨慎行事。